Plain-English translation of NCT06672536 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1/2 โ A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new medication that is injected directly into the eye to treat neovascular age-related macular degeneration (nAMD)โa condition where abnormal blood vessels grow under the retina and damage your central vision. Researchers want to find the safest and most effective dose of this medication and learn how well it works compared to an existing treatment already approved for this disease.
nAMD is a leading cause of vision loss in older adults, and while some treatments exist, they don't work for everyone or may not work well enough. This trial is exploring whether this new treatment could offer patients a better option to slow or stop vision loss.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this trial, you will receive injections of the study medication directly into your eye once every 4 weeks for a total of three injections. You will be assigned to receive one of three different doses of the new medication, or you may receive an existing approved treatment as a comparison. Throughout the study, you will have regular eye exams, vision tests, and imaging to monitor how the treatment is working and check for any side effects.
AI-generated summary from trial data ยท Jun 9, 2026 ยท Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Sinocelltech Ltd.
Collaborators
Tianjin Medical University Eye Hospital
Enrollment target
~82 participants
Started
November 2024
Primary completion
September 2026
This trial's estimated completion date has passed โ the record may not be fully up to date.
Age range
45 Years โ 80 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Li Xiaorong
Sinocelltech Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.